



Wallonia, a powerful ecosystem
to boost cell therapy products
development and manufacturing

WWW.BIOWIN.ORG

BiOWin

THE HEALTH CLUSTER OF WALLONIA

CELL THERAPY IN WALLONIA

From Academic Excellence to Industrial Expertise

EXCELLENCE IN ACADEMIC AND CLINICAL RESEARCH

- **5 Universities:** UCLouvain, ULB, ULiège, UMONS and UNAMUR with more than **30 laboratories** active in cell therapy and related domains.
- **More than 20 000 hospital beds** available for clinical trials.

INDUSTRIAL LEADERSHIP

- **7 companies:** Bone Therapeutics, Celyad Oncology, ERC Belgium, Novadip Biosciences, PDC*Line Pharma, Promethera Biosciences and Revatis developing cell therapy based products.
- **240 FTE**

HIGH QUALITY MANUFACTURING FACILITIES

- **Catalent:** ATMP-dedicated CDMO. GMP Facility.
- **Cell & Gene Therapy Lab (LTCG) of the CHU Liège:** CDMO for ATMP-manufacturing & import, GMP space rental and FAMHP-approved tissue banks (cord blood, hematopoietic stem cells and non-hematopoietic cells).
- **Skeletal Cell Therapy Support**








WALLONIA: A MATURE ECOSYSTEM TO DEVELOP AND MANUFACTURE YOUR CELL THERAPY PRODUCTS

- **Strong financial support** to innovation in health from the Regional Government.
- **Favorable tax** environment and R&D incentives.
- **Public and private investments funds** (university funds, regional and sub-regional funds, venture capital, international VCs...) to support innovation in health.
- **Excellence** in academic research and clinical development with **fastest approval** process in Europe for Phase I clinical trials (2 weeks).
- **An expertise in CAR-T cell therapy** and collaboration between industries and university hospitals.
- **European leadership** in industrialisation of cell therapy products.
- **Large capacities** for manufacturing cell therapy products.
- **Solid ecosystem** with a larger range of support services companies and **5 science parks**.
- **Relevant education and training programs** to answer specific needs in the cell therapy sector.
- **Connection with national and international networks** dedicated to regenerative medicine (Alliance for Regenerative Medicine).



BOWIN, THE HEALTH CLUSTER OF WALLONIA, A KEY PARTNER IN THE CELL THERAPY COMMUNITY

The cluster is at the heart of a strong and fully integrated ecosystem from bench to market. It's role is to build the bridges between the actors both at the local and the international level to foster innovation in Cell Therapy.

CELL THERAPY COMPANIES: KEY FIGURES

Company	Year of creation	Therapeutic domain	Cell type	Clinical phase	1st product on the market
 Bone Therapeutics	2006	Orthopaedics & bone diseases	Bone cell therapy products derived from bone marrow - MSC	Entering Phase III	> 2020
 Celyad Oncology	2007	Cancer	CAR-T cells using NK cells receptor	Phase I/II	2020
 ERC European Research Council	2008	Cancer (brain)	Tumor	Phase II	NA
 NOVADIP Innovative Cell Therapy	2013	NVD001-3D osteogenic structure for severe bone reconstruction and NVD002-biological bandage for wound healing	Adipose stem cells	Phase I/II	>2020
 PDC ^{line} Pharma ADVANCED CANCER VACCINES	2014	Oncology: Non Small Cells lung cancer and melanoma	Allogeneic Cell line of plasmacytoid dendritic cells (PDC)	Phase Ib/II	2025
 PROMETHERA BIOSCIENCES	2009	Acute on Chronic Liver Failure (ACLF) Non-alcoholic Steatohepatitis (NASH) Urea Cycle Disorders (UCD)	Allogeneic liver-derived mesenchymal stem cells and progenitor cells TNF-R1 antibodies	Phase II	2023
 RevaTis	2003	Veterinary regenerative medicine – preventive biobanking and therapeutic products for tendinopathies and arthropathies	Skeletal muscle derived mesenchymal stem cells	Clinical trial on tendonitis in progress, Clinical trial on osteoarthritis on demand	2020

MANUFACTURING FACILITIES: KEY FIGURES

C(D)MO	Year of creation	Cell type	Surface (m ²)
 Catalent	2011	Any types (MSCs, T cells, DCs, CAR T, TIL, TCR, etc.)	600+600
 LTCG CHU Université de Liège GIGA Institute	2002	Any types (MSCs, T cells, DCs, CAR T, TIL, TCR, etc.)	220
Skeletal Cell Therapy support	2011	Differentiated bone-forming cells derived from bone-marrow MSC	3000

LANDSCAPE IN THE VALUE CHAIN OF CELL THERAPY

RESEARCH



PRODUCTION, EQUIPMENT, AUTOMATION, ENGINEERING



QC, QA, REGULATORY



PROJECT MANAGEMENT, LOGISTICS



SCIENCE PARKS & ASSOCIATED ORGANISATIONS



Disclaimer: not exhaustive



BIOWIN ASBL

Maison de l'Industrie Technologique - Rue Auguste Piccard, 20 - 6041 Gosselies

Tel.: +32 71 919 285 • e-mail: contact@biowin.org • marianne.ghyoot@biowin.org

See our website www.biowin.org to access the list of all our members

Follow us on twitter: @BioWin_asbl & LinkedIn: BioWin

Wallonia.be

